Related Experiment Videos
[Lymphomatoid granulomatosis--remission induction with interferon-alpha 2b]
C Richter1, A Schnabel, K M Müller
1Poliklinik für Rheumatologie und Rheumaklinik Bad Bramstedt, Institut für Pathologie, Berufsgenossenschaftliche Kliniken Bergmannsheil der Ruhr-Universität, Bochum.
Deutsche Medizinische Wochenschrift (1946)
|October 27, 1997
Summary
Lymphomatoid granulomatosis (LG) in a 72-year-old woman with polyneuropathy was treated effectively with alpha-interferon (IFN-alpha). This suggests IFN-alpha is a safer alternative for early-stage LG compared to traditional treatments.
Area of Science:
- Pulmonology
- Neurology
- Oncology
Background:
- Lymphomatoid granulomatosis (LG) is a rare lymphoproliferative disorder.
- It can affect multiple organs, including the lungs and peripheral nervous system.
- Early diagnosis and treatment are crucial for managing LG.
Observation:
- A 72-year-old woman presented with nonproductive cough, sensorimotor axonal polyneuropathy, fatigue, and significant weight loss.
- Chest imaging revealed multiple lung nodules.
- Open lung biopsy showed pleomorphic angioinvasive lymphocytic infiltrations consistent with LG.
Findings:
- The patient was diagnosed with lymphomatoid granulomatosis (LG), with exclusion of Wegener granulomatosis.
- Treatment with alpha-interferon (IFN-alpha) resulted in complete remission within 4 months.
- Treatment interruption led to immediate disease recurrence, highlighting the need for sustained therapy.
Implications:
- Alpha-interferon (IFN-alpha) shows promise as a less toxic therapeutic option for early-stage LG.
- IFN-alpha may offer an alternative to cyclophosphamide and corticosteroids.
- Further research is warranted to establish IFN-alpha's role in LG management.